Patents by Inventor Fuminori Kawabata

Fuminori Kawabata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THERAPEUTIC OR PROPHYLACTIC AGENT FOR CORNEAL EPITHELIUM DISORDERS AND/OR CONJUNCTIVAL EPITHELIUM DISORDERS
    Publication number: 20160067204
    Abstract: The present invention provides an effective and safe prophylactic and therapeutic pharmaceutical agent and supplement for corneal epithelium disorders and/or conjunctival epithelial disorders. This is a therapeutic and/or prophylactic agent for corneal epithelium disorders and/or conjunctival epithelial disorders comprising eicosapentaenoic acid and/or docosahexaenoic acid, a glycerin ester or phospholipid comprising these fatty acids as constituent fatty acids, or a lower alcohol ester of these fatty acids as active ingredients. These preferably comprise EPA and/or DHA in the form of a refined fish oil or refined krill oil. A total of at least approximately 50 to 5,000 mg of EPA and/or DHA or the esters thereof are taken daily, thereby easing corneal epithelium disorders and/or conjunctival epithelial disorders. In addition, the amount of tears may be recovered.
    Type: Application
    Filed: November 16, 2015
    Publication date: March 10, 2016
    Inventors: Akiko HARAUMA, Fuminori KAWABATA, Toru MORIGUCHI, Tetsuya KAWAKITA, Kazuo TSUBOTA
  • THERAPEUTIC OR PROPHYLACTIC AGENT FOR CORNEAL EPITHELIUM DISORDERS AND/OR CONJUNCTIVAL EPITHELIUM DISORDERS
    Publication number: 20130245119
    Abstract: The present invention provides an effective and safe prophylactic and therapeutic pharmaceutical agent and supplement for corneal epithelium disorders and/or conjunctival epithelial disorders. This is a therapeutic and/or prophylactic agent for corneal epithelium disorders and/or conjunctival epithelial disorders comprising eicosapentaenoic acid and/or docosahexaenoic acid, a glycerin ester or phospholipid comprising these fatty acids as constituent fatty acids, or a lower alcohol ester of these fatty acids as active ingredients. These preferably comprise EPA and/or DHA in the form of a refined fish oil or refined krill oil. A total of at least approximately 50 to 5,000 mg of EPA and/or DHA or the esters thereof are taken daily, thereby easing corneal epithelium disorders and/or conjunctival epithelial disorders. In addition, the amount of tears may be recovered.
    Type: Application
    Filed: November 18, 2011
    Publication date: September 19, 2013
    Applicants: KEIO UNIVERSITY, NIPPON SUISAN KAISHA, LTD.
    Inventors: Akiko Harauma, Fuminori Kawabata, Toru Moriguchi, Tetsuya Kawakita, Kazuo Tsubota